2020
Mutant Isocitrate Dehydrogenase 1 Inhibitor Ivosidenib in Combination With Azacitidine for Newly Diagnosed Acute Myeloid Leukemia
DiNardo CD, Stein AS, Stein EM, Fathi AT, Frankfurt O, Schuh AC, Döhner H, Martinelli G, Patel PA, Raffoux E, Tan P, Zeidan AM, de Botton S, Kantarjian HM, Stone RM, Frattini MG, Lersch F, Gong J, Gianolio DA, Zhang V, Franovic A, Fan B, Goldwasser M, Daigle S, Choe S, Wu B, Winkler T, Vyas P. Mutant Isocitrate Dehydrogenase 1 Inhibitor Ivosidenib in Combination With Azacitidine for Newly Diagnosed Acute Myeloid Leukemia. Journal Of Clinical Oncology 2020, 39: 57-65. PMID: 33119479, PMCID: PMC7771719, DOI: 10.1200/jco.20.01632.Peer-Reviewed Original ResearchConceptsAcute myeloid leukemiaAdverse eventsQT prolongationMyeloid leukemiaMutant acute myeloid leukemiaBone marrow mononuclear cellsExpected safety profileIDH differentiation syndromeIntensive induction chemotherapyTreatment-related gradeMedian treatment durationPhase Ib trialComplete remission rateOverall response rateMarrow mononuclear cellsDifferentiation syndromeIb trialInduction chemotherapyOral ivosidenibSubcutaneous azacitidineComplete remissionComplete respondersRemission rateMedian durationOral inhibitor
2019
PS1023 MUTANT IDH1 INHIBITOR IVOSIDENIB (AG‐120) IN COMBINATION WITH AZACITIDINE FOR NEWLY DIAGNOSED ACUTE MYELOID LEUKEMIA
DiNardo C, Stein A, Stein E, Fathi A, Frankfurt O, Schuh A, Döhner H, Martinelli G, Patel P, Raffoux E, Tan P, Zeidan A, de Botton S, Kantarjian H, Stone R, Lam D, Wang X, Gong J, Kapsalis S, Hickman D, Zhang V, Winkler T, Wu B, Vyas P. PS1023 MUTANT IDH1 INHIBITOR IVOSIDENIB (AG‐120) IN COMBINATION WITH AZACITIDINE FOR NEWLY DIAGNOSED ACUTE MYELOID LEUKEMIA. HemaSphere 2019, 3: 460-461. DOI: 10.1097/01.hs9.0000562388.60660.bc.Peer-Reviewed Original ResearchAcute myeloid leukemiaOverall response rateMorphologic leukemia-free stateComplete remissionAdverse eventsFebrile neutropeniaCR rateMyeloid leukemiaMutant IDH1Isocitrate dehydrogenase 1Double-blind placebo-controlled studyGrade 3/4 adverse eventsRefractory acute myeloid leukemiaBone marrow mononuclear cellsCR/CRhGrade adverse eventsIDH differentiation syndromeIDH1 inhibitor ivosidenibMedian response durationPartial hematologic recoveryPhase 1b studyAbsolute neutrophil countPlacebo-controlled studyTreatment of adultsMarrow mononuclear cellsMutant IDH1 inhibitor ivosidenib (IVO; AG-120) in combination with azacitidine (AZA) for newly diagnosed acute myeloid leukemia (ND AML).
Dinardo C, Stein A, Stein E, Fathi A, Frankfurt O, Schuh A, Martinelli G, Patel P, Raffoux E, Tan P, Zeidan A, de Botton S, Kantarjian H, Stone R, Lam D, Gong J, Zhang V, Winkler T, Wu B, Vyas P. Mutant IDH1 inhibitor ivosidenib (IVO; AG-120) in combination with azacitidine (AZA) for newly diagnosed acute myeloid leukemia (ND AML). Journal Of Clinical Oncology 2019, 37: 7011-7011. DOI: 10.1200/jco.2019.37.15_suppl.7011.Peer-Reviewed Original ResearchAdverse eventsECG QTFebrile neutropeniaDouble-blind placebo-controlled studyGrade 3/4 adverse eventsBone marrow mononuclear cellsCR/CRhGrade adverse eventsIDH differentiation syndromeIDH1 inhibitor ivosidenibMedian response durationNon-intensive therapyPartial hematologic recoveryPhase 1b studyPlacebo-controlled studyAcute myeloid leukemiaMarrow mononuclear cellsAZA monotherapyD1-7Differentiation syndromeData cutoffHematologic recoveryMedian durationMedian timeSafety profile
2015
Niche-Dependent Growth of Malignant and Pre-Neoplastic Plasma Cells in Humanized Mice
Das R, Strowig T, Verma R, Koduru S, Hafemann A, Hopf S, Kocoglu M, Borsotti C, Zhang L, Branagan A, Eynon E, Manz M, Flavell R, Dhodapkar M. Niche-Dependent Growth of Malignant and Pre-Neoplastic Plasma Cells in Humanized Mice. Blood 2015, 126: 120. DOI: 10.1182/blood.v126.23.120.120.Peer-Reviewed Original ResearchBone marrow mononuclear cellsMultiple myelomaMarrow mononuclear cellsPlasma cellsPlasma cell tumorsInterleukin-6Tumor cellsAsymptomatic MMHumanized miceMononuclear cellsCell tumorsFlow cytometryPathogenesis of MMAsymptomatic multiple myelomaExtra-medullary sitesSetting of patientsHuman MM cellsInnate immune cellsPlasma cell disordersPlasma cell leukemiaPlasma cell cloneImmune-deficient miceHuman plasma cell tumorsInnate immune cell developmentSingle-cell mass cytometry
2013
Primary Marrow-Derived Stromal Cells: Isolation and Manipulation
Ramakrishnan A, Torok-Storb B, Pillai M. Primary Marrow-Derived Stromal Cells: Isolation and Manipulation. Methods In Molecular Biology 2013, 1035: 75-101. PMID: 23959984, PMCID: PMC3748384, DOI: 10.1007/978-1-62703-508-8_8.Peer-Reviewed Original ResearchConceptsMarrow stromal cellsStem cellsMSC populationsPrimary marrow stromal cellsMultipotent stem cellsImmortalized cell linesStromal cellsPrimary marrowMesenchymal lineagesCellular heterogeneityMesenchymal stem cellsHematopoietic cellsCell linesRare cellsCellsBone marrow mononuclear cellsMarrow mononuclear cellsBone marrow harvestLineagesBone marrowMarrow biopsyMononuclear cellsClinical transplantationMarrow harvestPopulation
2011
Challenging the Surgical Rodent Hindlimb Ischemia Model with the Miniinterventional Technique
Zhuang ZW, Shi J, Rhodes JM, Tsapakos MJ, Simons M. Challenging the Surgical Rodent Hindlimb Ischemia Model with the Miniinterventional Technique. Journal Of Vascular And Interventional Radiology 2011, 22: 1437-1446. PMID: 21459613, PMCID: PMC3367666, DOI: 10.1016/j.jvir.2010.12.039.Peer-Reviewed Original ResearchMeSH KeywordsAnimalsBlood Flow VelocityBone Marrow TransplantationChemokinesCytokinesDisease Models, AnimalEmbolization, TherapeuticFemoral ArteryHindlimbInflammation MediatorsIschemiaLaser-Doppler FlowmetryLigationMaleMuscle, SkeletalNeovascularization, PhysiologicRatsRats, Inbred LewRecovery of FunctionRegional Blood FlowTime FactorsConceptsMarrow mononuclear cellsLaser Doppler imagingRight femoral arterySurgical ligationFemoral arteryHindlimb ischemia modelSL groupInterventional embolizationIschemia modelBone marrow mononuclear cellsGranulocyte colony-stimulating factorPreserves tissue integrityColony-stimulating factorVivo microscopic imagesHindlimb ischemic modelChemokine assaysMassive scarringInflammatory infiltrationIL-18Lewis ratsNerve degenerationIL-13IL-6Mononuclear cellsIschemic model
2005
Generation of dendritic cells from rabbit bone marrow mononuclear cell cultures supplemented with hGM-CSF and hIL-4
Cody V, Shen H, Shlyankevich M, Tigelaar RE, Brandsma JL, Hanlon DJ. Generation of dendritic cells from rabbit bone marrow mononuclear cell cultures supplemented with hGM-CSF and hIL-4. Veterinary Immunology And Immunopathology 2005, 103: 163-172. PMID: 15621303, DOI: 10.1016/j.vetimm.2004.08.022.Peer-Reviewed Original ResearchConceptsBone marrow mononuclear cellsDendritic cellsDC vaccinesAllogeneic T cell proliferationCottontail rabbit papillomavirus modelDownregulation of CD14Therapeutic vaccination strategiesUseful preclinical dataMononuclear cell culturesT cell proliferationMHC class IIRabbit bone marrow mononuclear cellsMarrow mononuclear cellsRelevant animal modelsCytokines GM-CSFDC vaccinationCervical cancerLymphocyte reactionHuman papillomavirusMononuclear cellsPreclinical dataIL-4Vaccination strategiesNon-specific esterase activityAnimal models
This site is protected by hCaptcha and its Privacy Policy and Terms of Service apply